Nintedanib for progressive fibrosing interstitial lung disease: how many meet criteria in a UK district general hospital systemic sclerosis cohort?
作者信息
Ho Gen Nen, Douglas Karen May Jane
机构信息
Department of Rheumatology, The Dudley Group NHS Foundation Trust, Dudley, UK.
出版信息
Rheumatol Adv Pract. 2023 Apr 3;7(2):rkad037. doi: 10.1093/rap/rkad037. eCollection 2023.
Abstract
摘要
相似文献
1
Nintedanib for progressive fibrosing interstitial lung disease: how many meet criteria in a UK district general hospital systemic sclerosis cohort?尼达尼布用于进行性纤维化间质性肺病：在一家英国地区综合医院的系统性硬化症队列中，有多少患者符合标准？
Rheumatol Adv Pract. 2023 Apr 3;7(2):rkad037. doi: 10.1093/rap/rkad037. eCollection 2023.
2
Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.进行性纤维性间质性肺疾病：尼达尼布的新概念和适应证。
Mod Rheumatol. 2021 Jan;31(1):13-19. doi: 10.1080/14397595.2020.1826665.
3
Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.尼达尼布治疗慢性纤维化间质性肺疾病患者的暴露-疗效分析。
Respir Med. 2021 Apr-May;180:106369. doi: 10.1016/j.rmed.2021.106369. Epub 2021 Mar 14.
4
Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.尼达尼布治疗慢性纤维化间质性肺疾病患者的暴露-安全性分析。
BMC Pulm Med. 2021 Jul 21;21(1):244. doi: 10.1186/s12890-021-01598-0.
5
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.尼达尼布治疗进行性肺纤维化间质性肺疾病患者- INBUILD 试验中按间质性肺疾病诊断的亚组分析：一项随机、双盲、安慰剂对照、平行组试验。
Lancet Respir Med. 2020 May;8(5):453-460. doi: 10.1016/S2213-2600(20)30036-9. Epub 2020 Mar 5.
6
Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis-associated interstitial lung disease.尼达尼布作为系统性硬化症相关间质性肺病治疗方法的评估原理。
J Scleroderma Relat Disord. 2019 Oct;4(3):212-218. doi: 10.1177/2397198319841842. Epub 2019 Apr 21.
7
Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial.尼达尼布治疗自身免疫性疾病相关进行性纤维化间质性肺疾病患者：INBUILD 试验的亚组分析。
Arthritis Rheumatol. 2022 Jun;74(6):1039-1047. doi: 10.1002/art.42075. Epub 2022 May 2.
8
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.尼达尼布治疗进行性纤维化间质性肺疾病。
N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29.
9
Effects of nintedanib on disease progression and safety in Japanese patients with progressive fibrosing interstitial lung diseases: Further subset analysis from the whole INBUILD trial.尼达尼布对进行性纤维化间质性肺疾病日本患者疾病进展和安全性的影响：来自整个 INBUILD 试验的进一步亚组分析。
Respir Investig. 2022 Nov;60(6):787-797. doi: 10.1016/j.resinv.2022.06.009. Epub 2022 Aug 1.
10
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases.尼达尼布与进展性肺纤维化间质性肺疾病的免疫调节治疗。
Respir Res. 2021 Mar 16;22(1):84. doi: 10.1186/s12931-021-01668-1.
本文引用的文献
1
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.特发性肺纤维化（更新版）和成人进展性肺纤维化：美国胸科学会/欧洲呼吸学会/日本呼吸学会/拉丁美洲胸科学会临床实践指南。
Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47. doi: 10.1164/rccm.202202-0399ST.
2
Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry.前瞻性登记研究中进行性纤维化间质性肺疾病的患病率及特征
Eur Respir J. 2022 Oct 6;60(4). doi: 10.1183/13993003.02571-2021. Print 2022 Oct.
3
Outcomes and Incidence of PF-ILD According to Different Definitions in a Real-World Setting.真实世界中根据不同定义的PF-ILD的结局和发病率
Front Pharmacol. 2021 Dec 17;12:790204. doi: 10.3389/fphar.2021.790204. eCollection 2021.
4
Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study).法国进行性纤维性间质性肺病的流行病学、死亡率和疾病负担评估（PROGRESS 研究）。
Respir Res. 2021 May 24;22(1):162. doi: 10.1186/s12931-021-01749-1.
5
The burden of progressive fibrotic interstitial lung disease across the UK.英国进行性纤维性间质性肺疾病的负担。
Eur Respir J. 2021 Jul 8;58(1). doi: 10.1183/13993003.00221-2021. Print 2021 Jul.
6
Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey.评估进行性纤维化性间质性肺病的患病率：系统文献复习和医生调查数据。
Adv Ther. 2021 Feb;38(2):854-867. doi: 10.1007/s12325-020-01578-6. Epub 2020 Dec 14.
7
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.尼达尼布治疗进行性纤维化间质性肺疾病。
N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29.
Zotero 插件